The 2A Pharma Business
2A Pharma aims to meet and balance both pressing medical needs and the needs of our shareholders, by focusing on areas that are currently unmet or poorly served by existing vaccine technology. We aim to exploit every opportunity presented by the patented AAVLP technology to deliver safer, more effective solutions to more people, with worldwide exclusive rights to the platform. Our strategy is to focus first on vaccines that can illustrate the diverse and powerful potential of the technology, showing application across infectious disease, cancer, and autoimmune areas, before expanding to cover the many specific indications of each. We have currently identified over 60 potential indications and targets for the AAVLP technology platform, worth many tens of billions of dollars.
Join our Investor family
2A Pharma has enjoyed much success to date in raising seed investment of EUR 7.9m from family offices and is currently seeking Series A investment of between EUR 15-20m to fund phase 2 studies for alpha-HPV and beta-HPV vaccine development, and to progress the pipeline candidates to be IND-ready. We will be planning for a Series B or IPO in 2024. The successful phase 1 clinical trial of the HPV L2 vaccine candidate proved the effectiveness of the technology and its ability to protect across a wide range of HPV types with just one AAVLP particle type. This has opened up the door to development of single vaccines to target multiple variations of many conditions with just one vaccine each. 2A Pharma is rapidly pursuing a number of these with the greatest potential and patient need. We welcome too the opportunity to work with partners who can fund the discovery and proof-of—concept phases of vaccines for specific conditions, such as with Eurostars, who have funded EUR 653,000 to develop a therapeutic head and neck cancer vaccine.
Partner for Success
2A Pharma works in partnership with many collaborators worldwide, with class leading technologies and services for vaccine development and with partners for specific indications. We remain vigilant to discover new partnerships to develop new innovative future applications.